Biology subjects

Medard, G.

Publications and source records attributed to Medard, G..

4 recordsLinked to original sources

bioRxiv2026

Chemoproteomics identifies a pyrimidopyrimidine analogue as a tubulin-tyrosine ligase binder

Small-molecule drug discovery relies on identifying compounds that modulate specific protein targets, a process often hindered by cellular complexity. Through phenotypic screening of a kinase-focused diazaquinazoline library, we serendipitously identified CEM198 as the first high-affinity ligand of tubulin-tyrosine ligase (TTL). Functional assays combining live-cell TTL inhibition, microtubule polymerization, cell cycle analysis, and proteomics revealed that CEM198 acts through a dual mechanism: directly binding to TTL and altering /{beta}-tubulin conformation. This interaction restricts -tubulin tyrosination and disrupts tubulin polymerization, leading to microtubule destabilization. The differential effects observed between SH-SY5Y and HEK293T cells indicate that effective TTL inhibition depends on both direct binding and structural modulation of the tubulin heterodimer. These findings introduce CEM198 as a chemical probe for investigating the tubulin tyrosination-detyrosination and demonstrate the potential of chemoproteomics to uncover novel modulators of microtubule dynamics.

biochemistry↗

bioRxiv2025

Learning the Unseen: Data-Augmented Deep Learning for PTM Discovery with Prosit-PTM

Post-translational modifications (PTMs) are critical regulators of protein function, yet confidently identifying and localizing PTM sites across proteomes remains a challenging task. Integrating peptide property predictions into spectrum interpretation improves identification performance, but training data enabling zero-shot prediction across diverse PTMs are scarce. Here, we present a major expansion of the ProteomeTools dataset, comprising over 977,000 synthetic peptides, covering 22 PTM-residue combinations. Furthermore we developed Prosit-PTM, a model with chemically-informed encoding and amino acid substitution-based augmentation trained with our novel ground-truth dataset, that achieves accurate zero-shot predictions. Applied to modified peptides, Prosit-PTM enhances PTM-site localization in phosphoproteomics, increases identification of multiply modified peptides in histones, and enables data-driven rescoring for unseen modifications such as HLA peptides. Furthermore, the learned embeddings of amino acids and modifications capture physicochemical relationships underlying PTM-driven HLA presentation. Prosit-PTM is integrated into multiple open-source tools enabling PTM-aware rescoring, site localization, spectral library generation, and beyond.

bioinformatics↗

bioRxiv2025

High-throughput chemical proteomics workflow for profiling protein citrullination dynamics

Citrullination is a post-translational modification implicated in autoimmune and inflammatory diseases, yet its low abundance and lack of effective enrichment tools have limited proteome-wide analysis. Here, we developed a robust chemical proteomics workflow with improved specificity and throughput. This method builds upon glyoxal-based derivatization and incorporates a cleavable biotin linker for efficient peptide enrichment, release, and identification via mass spectrometry. Benchmarking across biological systems demonstrated a >10-fold increase in the detection of citrullinated peptides (> 150-fold increase in intensity) at sub-0.1% abundance. Applying the workflow to mouse brain tissue and human primary neutrophils revealed dynamics and condition-specific changes in the citrullinome, including previously uncharacterized sites and regulatory processes. Notably, extensive citrullination of linker histone H1 and structural proteins such as lamin B1 in ionomycin-activated neutrophils suggests broad remodeling of cell architecture via citrullination. This workflow enables proteome-wide mapping of citrullination sites and facilitates its study across diverse biological contexts.

biochemistry↗

bioRxiv2022

Hemisynthetic derivatives of the natural alkaloid trilobine are fast-acting antimalarial compounds with sustained activity in multi-drug resistant P. falciparum isolates

Malaria eradication requires the development of new drugs to combat drug-resistant parasites. The search for new chemical scaffolds that target novel pathways of the human malaria parasite Plasmodium falciparum is of highest priority. We identified bisbenzylisoquinoline alkaloids isolated from Cocculus hirsutus. (trilobine derivatives) as active in the nanomolar range against P. falciparum blood stages. Synthesis of a library of 94 hemi-synthetic derivatives allowed us to identify compound 84 that kills multi-drug resistant clinical isolates in the nanomolar range (median IC50 ranging from 35-88nM). Efforts were made to obtain compounds with significantly improved preclinical properties. Out of those, compound 125 delays the onset of parasitemia in P. berghei infected mice and inhibits P. falciparum transmission stages in vitro (culture assays) and in vivo using membrane feeding assay in the Anopheles stephensi vector. Compound 125 also impairs P. falciparum development in sporozoite-infected hepatocytes, in the low micromolar range. Finally, we used a chemical pull-down strategy to identify potential protein targets of this chemical family. Mass spectrometry analysis identified the parasite interactome with trilobine derivatives, identifying protein partners belonging to metabolic pathways that have not been previously targeted by antimalarial drugs or implicated in drug-resistance mechanisms.

pathology↗